Novartis Brasil

What Novartis Brasil does

Novartis Brasil (legal entity: Novartis Biociências S.A.) is the Brazilian commercial subsidiary of the Swiss-headquartered global pharmaceutical company Novartis AG (NYSE: NVS). Operating from São Paulo since 1996, the entity markets and distributes a portfolio of innovative prescription medicines across seven therapeutic areas: cardiology (Entresto, Sybrava), dermatology (Cosentyx, Xolair), hematology (Fabhalta, Jakavi), neurology (Kesimpta), oncology (Kisqali, Pluvicto), pneumology (Xolair), and rheumatology (Cosentyx). Its customer base spans patients and caregivers, prescribing healthcare professionals, and institutional healthcare administrators, with primary revenue derived from prescription pharmaceutical sales channeled through pharmacies, hospitals, and clinical settings.

The business operates a multi-platform digital ecosystem supporting its commercial model, including Portal Novartis (portal.novartis.com.br) for healthcare-professional registration, NovartisPro Brasil as the redesigned product and training hub, and MedHub Novartis Brasil, alongside the INFOMEC medical-scientific information service. Beyond the medicines themselves, the company layers value through patient support programs (Bem Estar and Vale Mais Saúde) and the Carreta da Saúde mobile health unit. Product pricing is not publicly disclosed; revenue figures are reported only at the Novartis AG consolidated level, and no subsidiary-level financial data is available in the source material.

As a wholly-owned operating subsidiary of Novartis AG rather than an independent corporate entity, Novartis Brasil's strategic direction, R&D pipeline, capital allocation, and senior leadership are determined at the parent level. The Brazilian entity's role is commercial execution, regulatory liaison with ANVISA, healthcare-professional engagement, and patient access support within the Brazilian market, leveraging the parent's global R&D, manufacturing, and intellectual-property base. No independent management team, funding history, or M&A activity is disclosed for the subsidiary.

Name

Novartis Brasil

Legal name

Novartis Biociências S.A.

Website

https://novartis.com.br

Company type

Private

Operating status

Operating

Headcount range

251–500 employees

Short description

Novartis Brasil (Novartis Biociências S.A.) is the Brazilian subsidiary of Novartis AG, commercializing innovative prescription pharmaceutical therapies across seven therapeutic areas to patients, healthcare professionals, and hospital systems throughout Brazil.

Ownership category

akta.pro rank

Product category

Prescription Pharmaceuticals

NAICS

Medicinal and Botanical Manufacturing (325411), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Innovative pharmaceuticals
• Prescription medicines
• Oncology treatments
• Cardiology drugs
• Patient support programs

Headquarters

HQ city

São Paulo

HQ country

Brazil

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations, Others

Distribution channels4 records

Marketing channels8 records

Core offering

Novartis Brasil develops, manufactures, and commercializes innovative prescription pharmaceutical products across seven therapeutic areas (cardiology, dermatology, hematology, neurology, oncology, pneumology, and rheumatology) for the Brazilian market. It operates dedicated digital portals for healthcare professionals (NovartisPro, Portal Novartis, MedHub) and runs patient support and community access programs (Bem Estar, Vale Mais Saúde, Carreta da Saúde).

Product overview

Novartis Brasil operates a multi-platform digital ecosystem for healthcare professionals and patients. The core offering includes a portfolio of innovative medicines across seven therapeutic areas: Cardiology (Entresto®, Sybrava®), Dermatology (Cosentyx®, Xolair®), Hematology (Fabhalta®, Jakavi®), Neurology (Kesimpta®), Oncology (Kisqali®, Pluvicto®), Pneumology (Xolair®), and Rheumatology (Cosentyx®). The company maintains three main digital platforms: Portal Novartis (portal.novartis.com.br) for healthcare professional registration and exclusive content, NovartisPro Brasil (pro.novartis.com/br-pt/) as the redesigned central hub for product information, training, and events, and MedHub Novartis Brasil. Patient support programs include Bem Estar and Vale Mais Saúde, while the Carreta da Saúde mobile unit provides community healthcare access.

Differentiator

Problem solved

Functional benefit

Products and services

• Entresto® Cardiovascular prescription medication used for treating heart failure and dyslipidemia, prescribed by cardiology specialists in Brazil.
• Sybrava® Cardiovascular prescription medication for lipid management, indicated for patients with lipid disorders.
• Cosentyx® Immunological prescription medication for treating hidradenitis suppurativa, psoriasis, and psoriatic arthritis.
• Xolair® Monoclonal antibody prescription medication for treating chronic spontaneous urticaria (CSU) and asthma.
• Fabhalta® Hematology prescription medication for treating paroxysmal nocturnal hemoglobinuria (PNH) and related hematological conditions.
• Jakavi® JAK inhibitor prescription medication for treating myelofibrosis and polycythemia vera.
• Kesimpta® Monoclonal antibody prescription medication for treating multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS).
• Kisqali® CDK 4/6 inhibitor prescription medication for treating hormone receptor positive (HR+) HER2 negative advanced or metastatic breast cancer.
• Pluvicto® Radioligand therapy for treating metastatic castration-resistant prostate cancer (mCRPC).
• Portal Novartis Centralized portal for healthcare professionals in Brazil providing access to product information, scientific resources, events, and services.
• NovartisPro Brasil Healthcare professional hub with redesigned interface providing access to product information, training materials, events, webinars, and service support across therapeutic areas in Brazil.
• MedHub Novartis Brasil Healthcare professional information platform operated by Novartis Brasil.
• Programa Bem Estar Patient support program offering treatment access assistance, adherence resources, and patient services in Brazil.
• Vale Mais Saúde Patient support program providing health-related benefits and assistance to patients in Brazil.
• Carreta da Saúde Mobile health unit program providing healthcare access and services to communities across Brazil.

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves6 records

Expansion highlights5 records

Direct peers

• GSK Brasil: GSK's Brazilian subsidiary competes in specialty pharma and respiratory (overlapping with Novartis Brasil's pneumology portfolio), and operates with a similar HCP engagement and pharmacy distribution model.
• Bayer Brasil: Bayer's Brazilian subsidiary overlaps with Novartis Brasil in cardiology, women's health, and specialty care, operating with similar multinational pharma distribution and prescriber engagement.
• MSD (Merck) Brasil: MSD's Brazilian subsidiary competes in oncology (Keytruda vs Kisqali/Pluvicto) and other specialty areas, operating with the same multinational pharma commercial structure and HCP engagement model as Novartis Brasil.
• Roche Brasil: Roche's Brazilian subsidiary competes directly with Novartis Brasil in oncology, neurology, and immunology with its own portfolio of innovative biologics and a comparable HCP engagement model. Same therapeutic-area focus on specialty biologics in the Brazilian market.
• Pfizer Brasil: Pfizer's Brazilian subsidiary offers a similarly broad innovative pharma portfolio spanning oncology, cardiology, immunology, and rare diseases, overlapping directly with Novartis Brasil's therapeutic-area footprint. Both operate large HCP-facing commercial and digital infrastructure in Brazil.
• AstraZeneca Brasil: AstraZeneca's Brazilian subsidiary is a direct competitor in oncology (overlapping with Kisqali), cardiology (overlapping with Entresto), and respiratory, with similar biologic and specialty pharma focus.
• Eli Lilly Brasil: Eli Lilly's Brazilian subsidiary competes with Novartis Brasil across oncology and specialty therapeutics, and operates with the same multinational innovative pharma distribution and HCP engagement infrastructure.
• AbbVie Brasil: AbbVie's Brazilian subsidiary is a direct competitor in immunology (Humira/Skyrizi vs Cosentyx) and neurology, with a comparable biologic-focused portfolio and HCP-driven specialty pharma commercial approach.
• Boehringer Ingelheim Brasil: Boehringer Ingelheim's Brazilian subsidiary competes with Novartis Brasil in cardiology and respiratory specialties, with a comparable multinational innovative pharma commercial structure.
• Sanofi Brasil: Sanofi's Brazilian subsidiary competes with Novartis Brasil across specialty care, immunology (Dupixent), rare diseases, and vaccines, using a comparable multinational pharmaceutical commercial model in Brazil.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/novartisbrasil

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Novartis Brasil